{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:31:17Z","timestamp":1773261077173,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10072-020-04494-3","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T01:02:10Z","timestamp":1591664530000},"page":"3697-3703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Thiazolidinedione use is associated with reduced risk of Parkinson\u2019s disease in patients with diabetes: a meta-analysis of real-world evidence"],"prefix":"10.1007","volume":"41","author":[{"given":"Salman","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambrish","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harveen","family":"Baxi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-6084","authenticated-orcid":false,"given":"Benny","family":"Antony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"4494_CR1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000445751","volume":"46","author":"L Hirsch","year":"2016","unstructured":"Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T (2016) The incidence of Parkinson\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology 46:292\u2013300","journal-title":"Neuroepidemiology"},{"key":"4494_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018969","volume":"8","author":"P Hobson","year":"2018","unstructured":"Hobson P, Meara J (2018) Mortality and quality of death certification in a cohort of patients with Parkinson\u2019s disease and matched controls in North Wales, UK at 18 years: a community-based cohort study. BMJ Open 8:e018969","journal-title":"BMJ Open"},{"key":"4494_CR3","unstructured":"Statistics. Parkinson\u2019s Foundation. Available at: https:\/\/www.parkinson.org\/Understanding-Parkinsons\/Statistics. Accessed on 10th July 2019"},{"key":"4494_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/jnnp-2015-312283","volume":"87","author":"F Moisan","year":"2016","unstructured":"Moisan F, Kab S, Mohamed F, Canonico M, le Guern M, Quintin C, Carcaillon L, Nicolau J, Duport N, Singh-Manoux A, Boussac-Zarebska M, Elbaz A (2016) Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry 87:952\u2013957","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4494_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mds.25328","volume":"28","author":"SJ Johnson","year":"2013","unstructured":"Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD (2013) An economic model of Parkinson\u2019s disease: implications for slowing progression in the United States. Mov Disord 28:319\u2013326","journal-title":"Mov Disord"},{"key":"4494_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mds.25292","volume":"28","author":"SL Kowal","year":"2013","unstructured":"Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A (2013) The current and projected economic burden of Parkinson\u2019s disease in the United States. Mov Disord 28:311\u2013318","journal-title":"Mov Disord"},{"key":"4494_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12955-017-0757-y","volume":"15","author":"G Velikova","year":"2017","unstructured":"Velikova G, Valderas JM, Potter C et al (2017) Proceedings of Patient Reported Outcome Measure\u2019s (PROMs) Conference Oxford 2017: advances in patient reported outcomes research. Health Qual Life Outcomes 15:185","journal-title":"Health Qual Life Outcomes"},{"key":"4494_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1046\/j.1471-4159.2002.00990.x","volume":"82","author":"T Breidert","year":"2002","unstructured":"Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson\u2019s disease. J Neurochem 82:615\u2013624","journal-title":"J Neurochem"},{"key":"4494_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1046\/j.1471-4159.2003.02210.x","volume":"88","author":"T Dehmer","year":"2004","unstructured":"Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson\u2019s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88:494\u2013501","journal-title":"J Neurochem"},{"key":"4494_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.neulet.2007.12.019","volume":"432","author":"RL Hunter","year":"2008","unstructured":"Hunter RL, Choi DY, Ross SA, Bing G (2008) Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 432:198\u2013201","journal-title":"Neurosci Lett"},{"key":"4494_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1742-2094-8-91","volume":"8","author":"CR Swanson","year":"2011","unstructured":"Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME (2011) The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 8:91","journal-title":"J Neuroinflammation"},{"key":"4494_CR12","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/mds.27128","volume":"32","author":"B Brakedal","year":"2017","unstructured":"Brakedal B, Fl\u00f8nes I, Reiter SF, Torkildsen \u00d8, D\u00f6lle C, Assmus J, Haugarvoll K, Tzoulis C (2017) Glitazone use associated with reduced risk of Parkinson\u2019s disease. Mov Disord 32:1594\u20131599","journal-title":"Mov Disord"},{"key":"4494_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/aje\/kwv109","volume":"182","author":"JG Connolly","year":"2015","unstructured":"Connolly JG, Bykov K, Gagne JJ (2015) Thiazolidinediones and Parkinson disease: a cohort study. Am J Epidemiol 182:936\u2013944","journal-title":"Am J Epidemiol"},{"key":"4494_CR14","doi-asserted-by":"publisher","first-page":"h3949","DOI":"10.1136\/bmj.h3949","volume":"351","author":"Z Kmietowicz","year":"2015","unstructured":"Kmietowicz Z (2015) Glitazones are associated with reduced risk of Parkinson\u2019s disease. Bmj 351:h3949","journal-title":"Bmj"},{"key":"4494_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1080\/07853890.2018.1488083","volume":"50","author":"H-L Lin","year":"2018","unstructured":"Lin H-L, Lin H-C, Tseng Y-F, Chao JC-J, Hsu C-Y (2018) Association of thiazolidinedione with a lower risk of Parkinson\u2019s disease in a population with newly-diagnosed diabetes mellitus. Ann Med 50:430\u2013436","journal-title":"Ann Med"},{"key":"4494_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001854","volume":"12","author":"R Brauer","year":"2015","unstructured":"Brauer R, Bhaskaran K, Chaturvedi N, Dexter DT, Smeeth L, Douglas I (2015) Glitazone treatment and incidence of Parkinson\u2019s disease among people with diabetes: a retrospective cohort study. PLoS Med 12:e1001854","journal-title":"PLoS Med"},{"key":"4494_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023302","volume":"8","author":"H-F Wu","year":"2018","unstructured":"Wu H-F, Kao L-T, Shih J-H et al (2018) Pioglitazone use and Parkinson\u2019s disease: a retrospective cohort study in Taiwan. BMJ Open 8:e023302","journal-title":"BMJ Open"},{"key":"4494_CR18","doi-asserted-by":"crossref","unstructured":"NINDS Exploratory Trials in Parkinson Disease (NET\u2010PD) FS\u2010ZONE Investigators (2015) Pioglitazone in early Parkinson\u2019s disease: a phase 2, multicentre, double-blind, randomised trial. The Lancet Neurology 14:795\u2013803","DOI":"10.1016\/S1474-4422(15)00144-1"},{"key":"4494_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269","journal-title":"Ann Intern Med"},{"key":"4494_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neulet.2018.02.027","volume":"671","author":"S Hussain","year":"2018","unstructured":"Hussain S, Singh A, Rahman SO, Habib A, Najmi AK (2018) Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: a meta-analysis of prospective studies. Neurosci Lett 671:120\u2013127","journal-title":"Neurosci Lett"},{"key":"4494_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jns.2017.09.026","volume":"381","author":"A Singh","year":"2017","unstructured":"Singh A, Hussain S, Najmi AK (2017) Number of studies, heterogeneity, generalisability, and the choice of method for meta-analysis. J Neurol Sci 381:347","journal-title":"J Neurol Sci"},{"key":"4494_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1517\/13543784.2015.963195","volume":"24","author":"AR Carta","year":"2015","unstructured":"Carta AR, Simuni T (2015) Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson\u2019s disease. Expert Opin Investig Drugs 24:219\u2013227","journal-title":"Expert Opin Investig Drugs"},{"key":"4494_CR23","doi-asserted-by":"publisher","first-page":"368ra174","DOI":"10.1126\/scitranslmed.aag2210","volume":"8","author":"A Ghosh","year":"2016","unstructured":"Ghosh A, Tyson T, George S et al (2016) Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson\u2019s disease. Science Translational Medicine 8:368ra174","journal-title":"Science Translational Medicine"},{"key":"4494_CR24","first-page":"4089214","volume":"2017","author":"Y Wang","year":"2017","unstructured":"Wang Y, Zhao W, Li G et al (2017) Neuroprotective effect and mechanism of thiazolidinedione on dopaminergic neurons in vivo and in vitro in Parkinson\u2019s disease. PPAR Res 2017:4089214","journal-title":"PPAR Res"},{"key":"4494_CR25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2337\/dc10-1333","volume":"34","author":"E Schernhammer","year":"2011","unstructured":"Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B (2011) Diabetes and the risk of developing Parkinson\u2019s disease in Denmark. Diabetes Care 34:1102\u20131108","journal-title":"Diabetes Care"},{"key":"4494_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","volume":"19","author":"JA Santiago","year":"2013","unstructured":"Santiago JA, Potashkin JA (2013) Shared dysregulated pathways lead to Parkinson\u2019s disease and diabetes. Trends Mol Med 19:176\u2013186","journal-title":"Trends Mol Med"},{"key":"4494_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/brain\/aws009","volume":"136","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Limousin P, Lees A, Foltynie T (2013) Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection. Brain 136:374\u2013384","journal-title":"Brain"},{"key":"4494_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","volume":"145\u2013146","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016) Insulin resistance and Parkinson\u2019s disease: a new target for disease modification? Progress in Neurobiology 145\u2013146:98\u2013120","journal-title":"Progress in Neurobiology"},{"key":"4494_CR29","first-page":"259","volume":"8","author":"E Hogg","year":"2018","unstructured":"Hogg E, Athreya K, Basile C, Tan EE, Kaminski J, Tagliati M (2018) High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson\u2019s disease. J Park Dis 8:259\u2013265","journal-title":"J Park Dis"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-020-04494-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T23:51:13Z","timestamp":1623196273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-020-04494-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4494"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04494-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"22 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}